The state of North Carolina currently has 38 active clinical trials seeking participants for Hypertension research studies. These trials are conducted in various cities, including Durham, Charlotte, Winston-Salem and Chapel Hill.
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients
Recruiting
Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO) Group 1 PAH.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Duke University Medical Center, Durham, North Carolina +1 locations
Conditions: PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Recruiting
TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).
Gender:
ALL
Ages:
Between 18 years and 83 years
Trial Updated:
04/10/2025
Locations: Durham, Durham, North Carolina
Conditions: Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension
Recruiting
This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/31/2025
Locations: Monroe Biomedical Research, Monroe, North Carolina
Conditions: Difficult to Control Hypertension
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
Recruiting
The primary objective of the THRIVE Pivotal study is to demonstrate the adjunctive effectiveness and the safety of the TIVUS system in: 1. subjects with hypertension (HTN) receiving up to 2 anti-hypertensive drugs of different classes in whom the anti-hypertensive medications will be stopped for a 4-week wash-out period before RDN/Sham procedure and during 2 months after procedure. 2. subjects with controlled hypertension receiving up to 2 anti-hypertensive drugs of different classes and who ac... Read More
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
03/19/2025
Locations: NC Heart and Vascular, Raleigh, North Carolina
Conditions: Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
ALL
Ages:
Between 0 years and 20 years
Trial Updated:
03/11/2025
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +1 locations
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Duke University Medical Center, Durham, North Carolina +2 locations
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients with PH-HFpEF
Recruiting
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/07/2025
Locations: Tenax Investigational Site, Durham, North Carolina +1 locations
Conditions: Pulmonary Hypertension
Pulmonary Artery DenerVation Clinical Study Using the Gradient Denervation System in Heart Failure Patients With Pulmonary Hypertension Group 2 (PreVail-PH2 Study)
Recruiting
This early feasibility study is intended to characterize the impact of pulmonary artery denervation on the quality of life in Heart Failure Patients with Group 2 Pulmonary Hypertension
Gender:
ALL
Ages:
Between 22 years and 85 years
Trial Updated:
03/03/2025
Locations: Duke University, Durham, North Carolina
Conditions: Group 2 Pulmonary Hypertension, Heart Failure
129Xe MRI Cardiopulmonary
Recruiting
The goal of this NIH-sponsored study is to characterize three biomarkers derived from 129Xe gas exchange MRI and to understand how they change in response to interventions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
A Phase 2a Study of LAM-001 for the Treatment of Pulmonary Hypertension
Recruiting
This is a clinical trial to assess the efficacy and safety of LAM-001 as an add-on therapy for the treatment pulmonary hypertension.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Pulmonary Hypertension
Remote Hypertension Management for Black Patients
Recruiting
This study will compare two approaches for managing hypertension in Black patients with uncontrolled blood pressure (BP). One approach will include home BP telemonitoring supported by a pharmacist and a community health worker. The other approach will include usual clinic-based care along with a home BP monitor and routine care.
Gender:
ALL
Ages:
Between 21 years and 85 years
Trial Updated:
02/06/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Uncontrolled Hypertension
Femoral Peri-arterial Local Anesthetic Injection Via Peri-arterial Perineural Catheter Reverses Tourniquet Associated Ischemic Hypertension
Recruiting
The goal of this prospective randomized double-blind study is to determine if an ultrasound guided peri-arterial injection of local anesthetic (LA) superomedially the femoral artery via peripheral nerve catheter reverses ischemic hypertension associated with prolonged lower extremity tourniquet time.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/03/2025
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Tourniquet Hypertension, Intraoperative Hypertension, Total Ankle Arthroplasty, Ankle Fusion